INTERPACE BIOSCIENCES, INC. - 8-K Filing

Interpace Biosciences reports Q3 2026 revenue of $10.4 million and Adjusted EBITDA of $2.1 million despite a net loss from continuing operations. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IDXG

Read the full article at SEC EDGAR

Part of the story Twist Bioscience Corp - 10-K Filing (3 articles)

More Regulatory news